Gloria Melanie 4

What Happened

• Gloria Melanie, Chief Operating Officer of Immunovant, was granted equity awards on April 7, 2026: 83,671 restricted stock units (RSUs) and 121,063 option awards (reported as a derivative). Both grants are reported at $0.00 cash consideration (typical for compensatory awards), so there was no purchase price paid by the insider.

Key Details

• Transaction date: 2026-04-07; Filing date (Form 4): 2026-04-09 (filed within the typical 2-business-day Form 4 deadline).
• Reported consideration: $0.00 for both the RSUs and the option awards (code A = award/grant).
• Vesting (per filing footnotes):
  • RSUs: 25% vest on April 1, 2027; remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to continued service.
  • Options: 25% vest on April 1, 2027; remaining 75% vest in 36 substantially equal monthly installments thereafter, subject to continued service.
• Shares owned after the transactions: not provided in the excerpt of the filing.
• No indication in the filing that awards were part of a 10b5-1 plan, a gift, a sale, or an exercise — these are compensatory grants.

Context

• RSUs are promises to deliver shares upon vesting; option awards are derivative rights to acquire shares in the future once vested. Neither represents an immediate sale or purchase of shares by the insider.
• These types of awards are standard executive compensation and do not by themselves signal buying or selling intent. Vesting is tied to continued service, so the economic benefit to the insider depends on future vesting and company stock performance.